Navigation Links
Quigley Corporation Announces Final Results of Quigley Pharma's Phase IIb Study
Date:7/22/2009

iminary analysis of the lack of adequate primary and secondary end point data indicates that the results may have been attributed to fewer then expected evaluable patients due to a shortage of drug and a high number of patients terminated early due to a lack of compliance with application and usage protocols.

"We have recently hired an independent consultant to conduct a thorough review of the entire research and development portfolio of potential products in the Quigley Pharma pipeline," said Ted Karkus, CEO. "We will wait for this review to be completed before determining the next steps in the development of QR-333 and other formulations."

All required end of study regulatory and reporting documentation and procedures will be completed. Consistent with previous announcements and pending the full review of the product portfolio, the Company will continue to consider licensing, partnering or collaborative relationship opportunities to further the development and potential commercialization of the QR-333 candidate and other formulations.

The ADA estimates that neuropathy occurs in up to 60-70% of diabetics, and an estimated 5 million Americans are affected by diabetic peripheral neuropathic pain. The World Health Organization estimates that more than 171 million people have diabetes worldwide, a figure that is expected to rise to 366 million by 2030.

About the study:

Methodology:

This was a double-blind, randomized, parallel-group, placebo controlled study conducted at 22 sites with 1 to 27 patients randomized per site. Patients between the ages of 18 and 70 years with a diagnosis of diabetes and symptoms of peripheral neuropathy were eligible for enrollment into the study. Eligible patients were randomized to 1 of 2 groups each applying study cream topically to the feet three times daily (tid) with placebo or QR-333 for
'/>"/>

SOURCE Quigley Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. Ted Karkus Named CEO of The Quigley Corporation; Robert V. Cuddihy, Jr. Named Chief Operating Officer
2. Dr. Richard Rosenbloom Resumes Services To The Quigley Corporations Pharma Subsidiary
3. Ted Karkus Appointed Interim Chief Executive Officer Of The Quigley Corporation
4. Ted Karkus and Karkus Slate of Directors Prevail in Federal Court, Seated as Directors of The Quigley Corporation; Ted Karkus Elected Chairman of the Board
5. The Quigley Corporation Announces Final Voting Results for 2009 Annual Meeting of Shareholders; Judge Orders Incumbent Board to Remain In Place Until Further Hearing; Final Outcome of Director Election Remains Uncertain
6. Dissident Stockholder Ted Karkus Found to Have Undisclosed Financial Arrangements With Dr. Richard A. Rosenbloom, COO Of Quigley Pharma, From 2008 to Date of Proxy: Rosenbloom Suspended Without Pay Pending Further Investigation
7. Karkus Nominees Caution Quigley Shareholders Not to be Fooled by the Companys Latest Announcement
8. The Quigley Corporation Announces Update on Strategic Alternatives and Commitment to Additional Review of Current Cost Structure
9. Judge Rejects Quigleys Claims - Karkus Director Candidates Prevail in Federal Court
10. Quigley Corporation Receives Support from Leading Independent Proxy Advisory Firms; RiskMetrics and Glass Lewis Reject Dissident Stockholder Ted Karkus, Citing Failure to Provide Detailed Business Plan
11. The Quigley Corporation Issues Open Letter to Stockholders; Urges Stockholders to Reject Dissident Ted Karkus Solicitation Efforts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2013)... The use of a smartphone application significantly ... new research presented today at Digestive Disease Week ... advance of the procedure, includes dietary restrictions and ... at strict intervals. The better the preparation, the ... and precancerous polyps in the colon. The study, ...
(Date:5/18/2013)... 2013 Assisted living and retirement ... safety and comfort of their residents. Systems Technologies ... with an effective and cost-efficient solution – VisionLink ... integrated, turnkey communications solution that helps nurses provide ... independence and privacy. , The VisionLink ...
(Date:5/18/2013)... 2013 The Communities of Distinction TV ... we call home. These are the townships, villages and other ... locations where the people are friendly and neighbors are there ... the highways and shares the best in both the United ... an American sports and film celebrity. It airs in May ...
(Date:5/18/2013)... TheBeautyPlace.com answers important questions about the hairloss ... a result of stress, nutrient deficiency or wearing a ... of men suffer from male patterned baldness. ... hair transplant surgery, but additionally carries a hair care ... Bosley Professional Strength. Their product line is a five-step ...
(Date:5/18/2013)... 18, 2013 Although obesity is associated ... association between obesity and esophageal adenocarcinoma, a type of ... tumors. As reported on Cancer.gov, last reviewed ... twice as likely as those of normal and healthy ... between obesity and esophageal cancer is not well understood, ...
Breaking Medicine News(10 mins):Health News:New smartphone application improves colonoscopy preparation 2Health News:VisionLink Nurse Call System's New Features Serve the Unique Needs of Retirement Communities 2Health News:VisionLink Nurse Call System's New Features Serve the Unique Needs of Retirement Communities 3Health News:Communities of Distinction TV Presents "A Place to Call Home" Segment 2Health News:TheBeautyPlace.com Features the Two New Best-Selling Hairloss Products: Bosley Professional Strength and Nioxin Systems 2Health News:TheBeautyPlace.com Features the Two New Best-Selling Hairloss Products: Bosley Professional Strength and Nioxin Systems 3Health News:hCGtreatments / Diet Doc Hcg Diets & Weight Loss Plans Announces New Prescription Hcg Diet Plans Designed to Trim Inches and Thus Reduce the Risk of Esophageal Cancer 2Health News:hCGtreatments / Diet Doc Hcg Diets & Weight Loss Plans Announces New Prescription Hcg Diet Plans Designed to Trim Inches and Thus Reduce the Risk of Esophageal Cancer 3
... the Royal College of Physicians (UK), the state of ... . , The audit entitled Myocardial Infarction National Audit ... in the percentage of people killed by heart attacks in ... years figures, meaning 12 more survivors for every 1,000 heart ...
... to new findings which refute the long-standing claim that ... the global population ,Organic farming can yield up to ... developing countries, as low-intensive methods on the same land. ... that in developed countries, yields were almost equal on ...
... used to be obsessed with the idea of shredding weight even ... that media reports about her being fat made her follow a ... I would beat myself up if I had some fat," US ... on her harsh weight control regime only when her sis Haylie ...
... former US surgeon general has launched a blistering attack ... downplayed several important health reports for political reasons . ... as the country's chief health educator from 2002 to ... discuss certain sensitive subjects in public. ,They ...
... in Lesotho have signed a declaration pledging to fight against ... Against AIDS (UNAIDS) said in a statement from Maseru on ... brings compelling urgency to the call for a renewed commitment ... HIV prevention, treatment, care and support as well as impact ...
... of puberty and maintenance of the female reproductive cycle ... that secrete gonadotropin-releasing hormone (GnRH). How signaling to these ... study appearing online on July 12 in advance of ... of Clinical Investigation, Sergio Ojeda and colleagues from Oregon ...
Cached Medicine News:Health News:Survey Shows Emergency Services Of British Hospitals Doing A Good Job 2Health News:Organic Farming can Feed the World, U-M Study Shows 2Health News:Organic Farming can Feed the World, U-M Study Shows 3Health News:White House Hid, Minimized Health Reports: Ex-surgeon General 2Health News:Senior Church Leaders in Lesotho Pledge to Fight AIDS 2
(Date:5/17/2013)... JERUSALEM , May 17, 2013 ... a developer of oral drug delivery systems, announced today ... has cleared the Company,s Investigational New Drug application(IND) for ... very pleased to have the FDA clearance to proceed," ... Oramed. "The upcoming trial is a major milestone for ...
(Date:5/17/2013)... Mass. , May 17, 2013  Boston Scientific ... participate at the annual EuroPCR Scientific Program May 21-24 ... are pleased to present a particularly rich and diversified ... Keith Dawkins , M.D., global chief medical ... trials will be presented, including the NG PROMUS trial, ...
(Date:5/16/2013)... Ill. and MECHELEN, Belgium ... GLPG) and AbbVie (NYSE: ABBV ) announced ... to include Crohn,s disease.  Galapagos will fund and complete ... designed to facilitate rapid progression into Phase 3.  Upon ... AbbVie will pay Galapagos $50 million.  The terms of ...
Breaking Medicine Technology:Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 2Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 3Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 2Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 3Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 4Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 5Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 6Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 7Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 8AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 2AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 3AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 4AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 5AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 6
... (SIX: RO, ROG; OTCQX: RHHBY) announced today that ... ChanTest Corporation, a leading ion channel screening provider, ... compounds using Roche,s xCELLigence System RTCA Cardio Instrument ... cell-derived cardiomyocytes provided by Cellular Dynamics International (CDI). ...
... Dec. 5, 2011  Radient Pharmaceuticals Corporation  (OTCQX:RXPC) (OTCPK:RXPC), ... Vitro Diagnostic (IVD) cancer test, announced today ... 2012 Gastrointestinal Cancers Symposium (ASCO Conference) were accepted ... meeting will be held on January 19-21, 2012 ...
Cached Medicine Technology:Roche, ChanTest Collaborate for Preclinical Cardiac Safety Testing of Drug Compounds Using iCell Cardiomyocytes and xCELLigence RTCA Cardio Instrument 2Roche, ChanTest Collaborate for Preclinical Cardiac Safety Testing of Drug Compounds Using iCell Cardiomyocytes and xCELLigence RTCA Cardio Instrument 3Roche, ChanTest Collaborate for Preclinical Cardiac Safety Testing of Drug Compounds Using iCell Cardiomyocytes and xCELLigence RTCA Cardio Instrument 4Radient Pharmaceuticals' Two Abstracts Submitted to 2012 Gastrointestinal Cancers Symposium (ASCO) Regarding Onko-Sure® Utility in Colorectal Cancer Are Accepted for Presentation 2Radient Pharmaceuticals' Two Abstracts Submitted to 2012 Gastrointestinal Cancers Symposium (ASCO) Regarding Onko-Sure® Utility in Colorectal Cancer Are Accepted for Presentation 3
Flag shaped sharp tip. Flat serrated handle with polished finish....
For use with E0828 A needle tip and E0828 B gouge tip. Round knurled with threaded ended for tips. Most popular size or model....
Threaded ends permit guarding the needle and gouge within the handle. Set consists of one each : E0828 A needle tip, E0828 B gauge tip and E0828 C handle. Most popular size or model....
Battery operated single speed motorized handpiece, tip cover, supplied with 0.5 mm tungsten burr (E0815 0.5) and one battery size "AA"....
Medicine Products: